Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
Novo Nordisk is cutting a lot of deals with small biotechs. The latest deal seeks to develop gene-editing therapies, perhaps for obesity.
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies
Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy. Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies.
Lose Weight With Novo Nordisk Drugs, Gain Money With Stock
Some experts believe Novo Nordisk A/S NVO products not only help people lose weight and control diabetes, they can help treat the country's addiction crisis.
Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
Novo Nordisk's blockbuster diabetes drug Ozempic may decrease the risk of opioid overdoses in certain patients, according to a new study. The results suggest semaglutide, the active ingredient in Ozempic, could potentially become a new alternative treatment for opioid use disorder, which could help address the ongoing opioid epidemic.
Novo Nordisk (NVO) Rises Higher Than Market: Key Facts
Novo Nordisk (NVO) closed at $125.44 in the latest trading session, marking a +1.41% move from the prior day.
Healthy Returns: Weight loss drug Wegovy could face Medicare price negotiations next
Novo Nordisk's weight loss drug Wegovy could face Medicare price negotiations next. Meanwhile, Particle Health files an antitrust suit against Epic Systems.
Novo Nordisk CEO testifies before Senate on weight loss drug prices
CNBC's Angelica Peebles reports on Novo Nordisk's testimony before the Senate Health, Education, Labor, and Pensions Committee.
Novo Nordisk's Setback Won't Last: A Game-Changing Drug Emerges
Novo Nordisk NYSE: NVO took a hit on its stock price last week after it received bad news on one of its in-development treatments. At the same time, shares of big and small competitors rallied as a result.
Novo Nordisk CEO set to defend Ozempic, Wegovy prices on Capitol Hill
The CEO of Novo Nordisk is set to face pointed questions on Capitol Hill Tuesday about the prices of the Danish pharmaceutical giant's blockbuster drugs Ozempic and Wegovy.
Novo Nordisk CEO to testify at Senate hearing over high weight loss drug prices
Novo Nordisk's top executive is slated to face a Senate grilling over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic. The Danish drugmaker's CEO, Lars Fruergaard Jørgensen, will testify at a Senate Health, Education, Labor and Pensions Committee hearing at 10 a.m.
Novo Nordisk CEO faces US Congress scrutiny over weight-loss drug pricing
U.S. Senator Bernie Sanders is set to question Novo Nordisk CEO Lars Jorgensen on Tuesday over the drugmaker's prices for its popular weight-loss and diabetes medicines that can cost Americans more than $1,000 a month.
Novo says Ozempic to be eligible for US price negotiations in less than a year
Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a year based on current criteria, the Danish drugmaker's CEO Lars Fruergaard Jorgensen said in his written testimony on Monday.
